Early stage researchers, including Phase I Clinics and Units, with limited resources now have access to a new eClinical research option designed to accelerate and enhance clinical operations. OmniComm Systems, Inc. (OTCQX: OMCM), a global provider of clinical data management technology, has launched TrialOne Express, (T1xpress), a prefab eClinical solution for Phase I clinic automation.
T1xpress provides preset configurations that will enable researchers with limited resources to automate their facilities and quickly launch clinical studies. These features include a preconfigured library, barcoded label templates, preset system roles and recruitment screens.
Additionally, T1xpress also provides data capture, sample tracking, data exporting and Exago custom reporting hosted in the OmniCloud. OmniComm will offer three locations for hosting support, with regional offices in the U.S., Europe and China. The package also includes standard process workflow diagrams, a validation starter kit and a “quick-start” implementation schedule.
“OmniComm’s TrialOne solution has been widely recognized as the most functionally robust Phase I clinic automation solution in the industry,” said Stephen Johnson, president and CEO of OmniComm. “However, the level of effort to implement such a robust solution and the hardware requirements necessary to host it have, in some cases, put it out of reach for some smaller Phase I clinics. This new prepackaged and fully hosted turnkey solution will allow for a much shorter implementation schedule, affording these smaller clinics all the benefits of a tier I solution at a much lower total cost of ownership.”
Please visit www.omnicomm.com for more information
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.